Canada markets close in 2 hours 4 minutes
  • S&P/TSX

    21,229.32
    -308.13 (-1.43%)
     
  • S&P 500

    4,581.82
    -81.03 (-1.74%)
     
  • DOW

    35,402.26
    -509.55 (-1.42%)
     
  • CAD/USD

    0.7974
    -0.0016 (-0.20%)
     
  • CRUDE OIL

    85.06
    +1.24 (+1.48%)
     
  • BTC-CAD

    52,168.03
    -1,022.25 (-1.92%)
     
  • CMC Crypto 200

    989.80
    -19.59 (-1.94%)
     
  • GOLD FUTURES

    1,812.70
    -3.80 (-0.21%)
     
  • RUSSELL 2000

    2,104.76
    -57.70 (-2.67%)
     
  • 10-Yr Bond

    1.8590
    +0.0870 (+4.91%)
     
  • NASDAQ

    14,547.34
    -346.41 (-2.33%)
     
  • VOLATILITY

    22.62
    +3.43 (+17.87%)
     
  • FTSE

    7,563.55
    -47.68 (-0.63%)
     
  • NIKKEI 225

    28,257.25
    -76.27 (-0.27%)
     
  • CAD/EUR

    0.7036
    +0.0035 (+0.50%)
     

Iveric Bio to Participate in the Credit Suisse 30th Annual Virtual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, November 03, 2021--(BUSINESS WIRE)--IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Glenn P. Sblendorio, Chief Executive Officer, and Pravin U. Dugel, M.D., President, will participate in a fireside chat at the Credit Suisse 30th Annual Virtual Healthcare Conference on Tuesday, November 9, 2021 at 11:20 a.m. ET.

An audio webcast of the fireside chat can be accessed on the Investor / Events & Presentations section of the Iveric Bio website at www.ivericbio.com. An archived replay of the presentation will be available on the Company’s website immediately following the conference and for at least 30 days thereafter.

About Iveric Bio
Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs. The Company is committed to having a positive impact on patients’ lives by delivering high-quality, safe and effective treatments designed to address debilitating retina diseases including all stages of age-related macular degeneration. For more information on the Company, please visit www.ivericbio.com.

Forward-looking Statements
Any statements in this press release or made during the presentation referenced herein about Iveric Bio’s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including those described in the "Risk Factors" section of public filings made by Iveric Bio with the U.S. Securities and Exchange Commission. Any forward-looking statements represent Iveric Bio’s views only as of the date of this press release or the presentation, as applicable. Iveric Bio anticipates that subsequent events and developments may cause its views to change. While Iveric Bio may elect to update these forward-looking statements at some point in the future, Iveric Bio specifically disclaims any obligation to do so unless required by law.

ISEE-G

View source version on businesswire.com: https://www.businesswire.com/news/home/20211103005029/en/

Contacts

Investor Contact:
Iveric Bio
Kathy Galante, 212-845-8231
Senior Vice President, Investor Relations
kathy.galante@ivericbio.com

or

Media Contact:
SmithSolve
Alex Van Rees, 973-442-1555 ext. 111
alex.vanrees@smithsolve.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting